gastric neuroendocrine tumor G1

Summary

gastric neuroendocrine tumor G1 (MONDO:0006227) is a cancer and 1 clinical trial. Top therapeutic interventions include bevacizumab and octreotide acetate. A subtype of carcinoid tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastric neuroendocrine tumor G1
Mondo ID	MONDO:0006227
EFO	EFO:1000275
NCIT	C4635
UMLS	C0349529
MedGen	83885
GARD	0024341
Anatomy (UBERON)	UBERON:0000945
Is cancer (heuristic)	yes

Also known as: gastric carcinoid tumor · gastric carcinoid tumour · gastric ECL cell NET · gastric ECL cell NET G1 · gastric ECL cell, histamine-producing NET · gastric ECL-cell carcinoid tumor · gastric ECL-cell carcinoid tumour · gastric enterochromaffin-like cell carcinoid tumor · gastric enterochromaffin-like cell carcinoid tumour · gastric enterochromaffin-like cell neuroendocrine tumor · gastric enterochromaffin-like cell neuroendocrine tumour · gastric NET G1 · grade 1 neuroendocrine neoplasm of stomach · stomach carcinoid tumor · stomach carcinoid tumour · stomach NET G1 · stomach neuroendocrine neoplasm G1 · stomach neuroendocrine tumor, well differentiated, low grade

Disease family

This is a subtype of carcinoid tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › neuroendocrine neoplasm › carcinoid tumor › gastric neuroendocrine tumor G1

Related subtypes (6): lung carcinoid tumor, atypical carcinoid tumor, somatostatinoma, intestinal neuroendocrine tumor G1, pancreatic neuroendocrine tumor G1, childhood carcinoid tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00569127	PHASE3	ACTIVE_NOT_RECRUITING	Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEVACIZUMAB	4	1
OCTREOTIDE ACETATE	4	1